azvudine + itraconazole

Azvudine + itraconazole is an investigational combination of two pharmaceutical agents, each with distinct mechanisms of action and indications. Azvudine is an antiviral nucleoside analog primarily developed for the treatment of HIV-1 and COVID-19. It acts as a reverse transcriptase and RNA-dependent RNA polymerase (RdRp) inhibitor, and is also being explored for antitumor activity. Itraconazole is a triazole antifungal agent used to treat various serious fungal infections by inhibiting fungal cytochrome P450-dependent lanosterol 14α-demethylase, interfering with ergosterol synthesis and cell membrane formation. The combination is being studied due to potential drug-drug interactions, as itraconazole is a potent inhibitor of the drug transporter P-glycoprotein (P-gp), and azvudine is a substrate and weak inducer of P-gp. This pairing is under evaluation to determine possible effects on azvudine’s pharmacokinetics and safety profile, especially in healthy subjects[3][5][7].

Brand names

Sporanox + none for azvudineOnmel + none for azvudine